8-K: Forian CEO-Led Group Bids $2.10/Share to Take Company Private

Forian Inc. announced its Board received an unsolicited, non-binding proposal from a group led by its CEO to take the company private at $2.10 per share.

Summary

• Forian Inc. received an unsolicited, preliminary, non-binding proposal on August 25, 2025, to be taken private.
• The proposal comes from a group led by Forian founder, Executive Chairman, and CEO Max Wygod, who, along with other participants, beneficially owns approximately 63% of the company's common stock.
• The proposed purchase price is $2.10 per share in cash for all outstanding shares not currently owned by the consortium.
• This offer represents a 19% premium to the closing price as of August 22, 2025.
• The Board of Directors has established a Special Committee of independent directors to evaluate the proposal with its own advisors.
• The proposal is conditioned on financing, satisfactory employment agreements, a definitive acquisition agreement, Special Committee approval, and acquisition of a majority of shares.
• The consortium believes going private will address low liquidity, slow value recognition, valuation disparity, and the burdens of public company reporting and compliance.

Sentiment

Score: 6

Explanation: The proposal offers a decent premium for shareholders and addresses perceived undervaluation and public company burdens. However, the non-binding nature and potential conflicts of interest from the CEO-led group introduce uncertainty. The score reflects a cautiously optimistic view for shareholders, assuming the deal materializes at the proposed price or higher.

Positives

• Provides immediate liquidity and certainty of value for public stockholders.
• Offers a substantial premium of 19% to the closing price as of August 22, 2025.
• The company would avoid the expense, distraction, and administrative burden of quarterly reporting and Sarbanes-Oxley compliance.
• The consortium is highly confident financing can be arranged on an expedited basis.
• No third-party consents or regulatory approvals are expected to be required.

Negatives

• The proposal is preliminary, non-binding, and unsolicited, with no assurance of a definitive offer or consummation.
• The CEO and other inside directors leading the proposal already own approximately 63% of the company, raising potential conflict of interest concerns.
• The "low float" and "slow recognition of value" cited as reasons for going private suggest the company may be undervalued in the public market.
• The transaction is conditioned on the negotiation and execution of satisfactory employment agreements with key management personnel, which could influence management's stance.

Risks

• There is no assurance that any definitive offer will be received, that any definitive acquisition agreement will be executed, or that this or any other transaction will be approved or consummated.
• The proposal is conditioned on the receipt of financing, which is not yet secured.
• The transaction is subject to satisfactory completion of customary due diligence by the consortium.
• Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the company's control and are not guarantees of future results.
• Potential risks and uncertainties are more fully set forth under "Risk Factors" in Forian's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

There can be no assurance that any definitive offer will be received, that any definitive acquisition agreement will be executed relating to the proposal, or that this or any other transaction will be approved or consummated. The company does not undertake any obligation to provide updates except as required by law.

Management Comments

• "We firmly believe that our proposed Transaction is in the best interests of Forian stockholders and other stakeholders, including its employees, clients, and end-users."
• "As a public company, Forian’s low float depresses liquidity, slows the recognition of value in the markets, and widens the valuation disparity between the Company and comparable private peers."
• "We do not believe that it makes sense for Forian, to be subject to the expense, distraction and administrative burden of quarterly reporting requirements and Sarbanes-Oxley compliance obligations."
• "The Transaction addresses these considerations while providing public stockholders with immediate liquidity and certainty of value at a premium to current trading levels."
• "Given our knowledge of the Company, we expect to be in a position to execute a definitive agreement promptly."
• "We are highly confident the financing can be arranged on an expedited basis."
• "Given our history with Forian, we anticipate that the remaining due diligence will be limited in scope and can be completed quickly, assuming that the requested information is provided in a timely manner."

Industry Context

Forian operates in the data science, information, and analytics solutions space, serving life science, healthcare, and financial services industries. The proposal to take the company private, citing low float and valuation disparity with private peers, suggests that the public market may not be fully appreciating the company's value or that the operational burdens of being public outweigh the benefits for a company of its size and market position. This trend of private equity or management-led buyouts is common for companies that believe they are undervalued or can achieve greater operational efficiency away from public scrutiny and compliance costs.

Corporate Governance

Related Party Transactions

• The proposal to take the company private is led by Forian's founder, Executive Chairman, and CEO Max Wygod, along with other inside directors (Adam Dublin and Shahir Kassam-Adams) and entities associated with them.
• This group beneficially owns approximately 63% of the company's common stock.
• The transaction is conditioned on the negotiation and execution of satisfactory employment agreements with key management personnel, which could include the proposing parties.

Stakeholder Impact

• Shareholders (excluding consortium): Potential for immediate liquidity and a 19% premium over recent trading prices, but also the loss of future public market upside if the company's value grows significantly in private hands.
• Consortium Members: Opportunity to gain full control of the company, potentially unlock value away from public market pressures, and avoid public company compliance costs.
• Employees: The proposal is conditioned on satisfactory employment agreements for key management, suggesting continuity for some, but broader employee impact is not detailed.
• Clients and End-Users: The consortium believes the transaction is in their best interests, implying potential for more focused operations or investment without public market distractions.

Next Steps

• The Special Committee of independent directors will evaluate the proposal and determine the appropriate course of action and process.
• The consortium will conduct confirmatory due diligence.
• Negotiation and execution of satisfactory employment agreements with key management personnel.
• Negotiation and execution of a definitive acquisition agreement.
• Receipt of financing for the transaction.
• Commencement of a tender offer to acquire outstanding shares, followed by a short-form merger.
• The consortium will promptly file a Schedule 13D.

Key Dates

Recommendation

The unsolicited, non-binding proposal offers a 19% premium, which is attractive for immediate liquidity. However, the deal is not guaranteed, and the involvement of the CEO and other insiders who already own a majority stake creates potential conflicts of interest. While the Special Committee is a positive step for governance, investors should hold to see if a definitive agreement is reached, if a higher offer emerges, or if the Special Committee rejects the proposal, as the current offer is preliminary and non-binding.

Keywords

Forian Inc., FORA, take-private, privatization, Max Wygod, tender offer, merger, special committee, data science, life science, healthcare, financial services, acquisition proposal, stock buyback, going private